Summary
60.71
0.20
(0.32%)
07/17/2026
Bristol-Myers Squibb Company (BMY)Key Facts
Performance
Historical returns1D
0.32%
1W
5.09%
1M
9.42%
3M
3.79%
6M
11.87%
1Y
34.44%
5Y
10.38%
Snapshot
Key statisticsClose
60.71
Change
0.20
Change %
0.32%
Open
61.07
Day Range
60.47 – 62.29
Volume
9,149,260
Avg Vol (20d)
13,337,767
Rel Vol
0.69x
52W Range
41.00 - 61.56
vs 52W High
-1.39%
vs 52W Low
48.08%
Gap
-0.40
Market Cap
USD 95.53B
Beta
0.31
Dividend Yield
5.34%
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 2× | 0.00% |
| 1-Month | 7× | 0.00% |
| 3-Month | 3× | 0.00% |
| 6-Month | 4× | -0.57% |
| YTD | 7× | -0.57% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 18× | -0.57% |
| 2-Year | 22× | -0.57% |
| 3-Year | 8× | -0.57% |
| 5-Year | 30× | -11.65% |
| 10-Year | 41× | -11.65% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 48.19B
-0.2% YoY
Net Income
USD 7.06B
-179.0% YoY
EPS
3.46
-178.5% YoY
Gross Margin
67.6%
Operating Margin
26.3%
Net Margin
14.6%
EBITDA
USD 14.55B
Free Cash Flow
USD 12.85B
26.7% margin
ROE
38.2%
ROA
7.8%
Debt / Equity
2.55x
net debt USD 36.93B
Cash & Equiv.
USD 10.21B
Fundamental Ratings
MainB+
RecommendedNeutral
DCFStrong Buy
ROEStrong Buy
ROABuy
Debt/EquityStrong Sell
P/ENeutral
P/BStrong Sell
Latest Earnings
- BMY reported last earnings on 2026-04-30.
- EPS of $1.58 vs $1.42 estimated — surprise $0.16.
- Revenue of $11,489M vs $10,927M estimated — surprise $562M.
News
All newsWhy the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to its last close.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb
Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment
The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.'s (NYSE:BMY) investigational oral therapy mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.
Start Investing At 60 And Retire On Dividends Forever
Retiring on dividends remains achievable for late starters by building a high-yield, quality portfolio targeting a 6% yield with safe, growing payouts. Dividend-focused strategies mitigate sequence of returns risk, enabling investors to live off income rather than depleting principal during market...
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
They may not remain cheap for too much longer.
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.
Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.
Bristol Myers Squibb: Pain First, Payoff Later?
Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth....
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of...
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines and medical technology.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck, AbbVie probed by US lawmakers over China clinical trials: report
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move from the previous day.